OATD-02 is an oral, potent and selective dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer Phase I clinical trial to assess safety, tolerability and preliminary efficacy of OATD-02 in patients with advanced and/or
Read moreDr Zbigniew Zasłona, PhD promoted to Chief Scientific Officer – Dr Zasłona remains a member of Molecure’s Management Board Dr Adam Gołębiowski transitioning from management board position to take on role of Senior Research Fellow
Read moreWarsaw, Poland – 5 December 2022 – Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein
Read moreOATD-02 is an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer. Phase I clinical trial to begin later in 2022 to assess safety, tolerability and efficacy
Read moreWarsaw, Poland – 14 November 2022 – Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored
Read moreMolecure Third Quarter 2022 Pipeline Highlights and Financial Results Proprietary pipeline progressing in-line with our strategic objectives for 2022-2025 Lead proprietary candidate, OATD-01 a novel chitinase inhibitor in sarcoidosis expected to advance into a Phase II
Read moreOur new name “Molecure” reflects expansion of scope of small molecule targets from novel proteins to mRNA in discovery & development of breakthrough therapies for multiple diseases Worldwide rights regained to novel, dual chitinase inhibitor OATD-01
Read moreOATD-02 is an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer. Following CTA approval, Molecure plans to initiate a Phase I clinical trial in late 2022
Read morePawel Trawkowski is graduate of faculty of Marketing and Management of Warsaw University with 25 years of managerial experience and broad knowledge acquired in largest international pharmaceutical companies. From 1997 to 2003 he was working in
Read more
